Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 54Other hematologic neoplasm 26Plasma cell 1Myeloid 1Head & Neck 1Genitourinary 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Primary Central Nervous System Lymphoma (PCNSL) 1

Interventions

Magnetic Resonance Spectroscopy 73Temozolomide 68Specimen Handling 48Radiotherapy 40Radiosurgery 29Bevacizumab 26Radiation 25Cyclophosphamide 25Nivolumab 21Biopsy 21pembrolizumab 20Carboplatin 16X-Rays 14Lomustine 13Ipilimumab 13fludarabine 12Irinotecan 12Vincristine 11Topotecan 11Surgical Procedures, Operative 11Cisplatin 11Blood Specimen Collection 11trametinib 9dinutuximab 9Immunoglobulin G 8Etoposide 8Doxorubicin 8lutetium Lu 177 dotatate 7fludarabine phosphate 7atezolizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ibrutinib × CNS × 90 days × Clear all
NCT07082868 2026-05-06

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
26 enrolled
CNSLymphoid

Primary Central Nervous System Lymphoma (PCNSL)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡